While mRNA vaccines have many advantages, they also face some challenges. One of the primary challenges is the requirement for cold storage, which can complicate distribution, especially in low-resource settings. For instance, the Pfizer-BioNTech vaccine initially required storage at ultra-low temperatures, although there have been advances to extend its stability at higher temperatures. Additionally, there are ongoing concerns about vaccine equity, as wealthier nations have had greater access to these vaccines compared to poorer countries.
